logo

Emergent Biosolutions Inc (EBS)



Trade EBS now with
  Date
  Headline
6/24/2022 6:34:23 AM Emergent BioSolutions: FDA Accepts For Review The BLA For AV7909 Anthrax Vaccine Candidate
5/16/2022 6:49:11 AM Emergent BioSolutions To Acquire Chimerix's Exclusive Worldwide Rights To TEMBEXA
3/11/2022 6:40:56 AM Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment For Cyanide Poisoning
1/14/2022 6:42:27 AM Emergent BioSolutions Says Fuad El-Hibri, Founder And Executive Chairman, Will Retire Effective April 1, 2022
12/16/2021 7:36:46 AM Emergent BioSolutions Doses First Patient In Phase 1 Study Of Universal Influenza Vaccine Candidate
10/15/2021 6:45:52 AM Emergent BioSolutions Begins Phase 3 Study Of Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
1/25/2021 8:53:50 AM Emergent, Humanigen Enter Contract Development And Manufacturing Services Agreement For Lenzilumab
8/7/2014 7:34:24 PM Emergent BioSolutions Inc (EBS) Has Raised Its 2014 Revenue Estimate To $425 - $450 Mln From $415 - $445 Mln
11/7/2013 6:36:18 PM Emergent BioSolutions Inc (EBS) Has Raised Its FY 13 Revenue Estimate To $300 - $310 Mln From $290 - $310 Mln
5/21/2012 7:01:30 AM EMERGENT BIOSOLUTIONS (EBS) Announces $35 Mln Stock Repurchase Plan
8/4/2011 6:52:53 PM EMERGENT BIOSOLUTIONS (EBS) Has Lowered Its FY11 Revenue Estimate To $270 - $290 Mln From $320 - $340 Mln
7/20/2010 7:30:26 AM EMERGENT BIOSOLUTIONS (EBS) Has Raised Its FY10 Revenue Estimate To $275 - $300 Mln From $235 - $255 Mln